A cannabis B2B supply agreement is the legal and operational backbone of any wholesale cannabis relationship in Canada. For Licensed Producers entering distribution arrangements with importers, pharmacy networks, or fellow LPs, the contract defines not just what gets shipped, but who absorbs regulatory risk, who bears the cost of a failed COA, and what happens when Health Canada amends an export permit condition mid-agreement.
Most supply disputes in the Canadian cannabis space do not begin with bad faith. They begin with contracts that treated price and volume as the only variables worth specifying. This guide breaks down what a well-structured B2B cannabis supply agreement covers, which compliance obligations belong in writing rather than in verbal assurances, and what contract provisions should concern any procurement lead reviewing a new LP relationship.
It is written for B2B buyers, procurement officers, and LP business development leads working within the framework of the Cannabis Act and Cannabis Regulations.
Why the contract structure matters more than the price
Price per gram gets the most attention in early LP negotiations. It also tends to be the least useful variable when a supply relationship breaks down. The questions that matter at that point are: whose quality specification governs, who carries the cost of a rejected batch, and what notice period applies if one party needs to exit.
Cannabis supply agreements operate inside a heavily regulated framework. The Health Canada licence held by both parties is not a background detail. It is a live condition. Either party's licence can be amended, suspended, or revoked, and any of those events affects the legal validity of the supply arrangement. A contract that treats the licence as assumed rather than verified is a contract that will create problems when it matters most.
Internationally, the structure becomes more complex. When a Canadian LP is shipping to a German importer, the agreement must account for Bundesopiumstelle import permit requirements, EU-GMP documentation obligations, and the possibility that a regulatory amendment in either jurisdiction mid-term changes what can be shipped, how, or at all. None of those variables are price. All of them belong in the contract.
The difference between an LP that can scale its B2B relationships and one that stays stuck in one-off spot purchases usually comes down to whether they have a supply agreement template they can stand behind. A well-structured contract is also a credibility signal during procurement review. See our guide on how buyers evaluate cannabis B2B suppliers to understand what procurement leads are looking for on the other side of the table.
Key clauses every cannabis supply agreement must include
The following provisions form the minimum viable structure for a compliant and operational cannabis B2B supply agreement. Each clause addresses a failure mode that commonly surfaces in supply disputes.
Product specification and quality thresholds
Define what is being supplied with precision: cultivar, format (bulk flower, pre-packaged, extract), minimum THC and CBD percentages, maximum residual solvent limits where applicable, and any format requirements (bud size, moisture content range). Referencing the COA from the most recent batch as an exhibit is standard practice and provides a concrete baseline for future deliveries.
Volume commitments and minimum purchase obligations
Specify whether the agreement is firm (take-or-pay) or indicative (best-efforts). Take-or-pay structures provide revenue certainty for the LP; best-efforts structures reduce buyer risk but offer weaker supply security. Offtake agreements tied to a specific grow cycle should define the harvest window, yield tolerance, and what happens if the LP's crop comes in short.
Delivery terms and transfer of title
Incoterms matter in cross-border cannabis supply. Specify whether title transfers at the LP's facility, at the border, or on delivery at destination. For export transactions, this determines who bears regulatory and insurance risk during transit. Canadian LPs exporting under Health Canada export permits should confirm that the permit conditions align with the chosen Incoterm before signing.
COA acceptance criteria and batch rejection process
Define the COA parameters that govern acceptance. Include the testing lab, the standard applied (ISO/IEC 17025 accreditation recommended), the tolerance range on potency, and the microbial and pesticide limits. Set a clear rejection window (typically 5 to 10 business days from delivery) and a process for disputed results, including a named arbitration lab. For background on what a compliant COA covers, see our post on stability and shelf-life testing for B2B buyers.
Pricing, payment terms, and currency provisions
Set the base price per gram or unit. Include a pricing review mechanism (annual, or tied to an index) for agreements longer than twelve months. For international agreements, specify the contract currency, which party bears foreign exchange risk, and payment terms relative to delivery or COA acceptance. Late payment provisions and interest rates belong here, not in a side letter.
Exclusivity and territory
If the buyer is seeking exclusivity in a market, define the geography precisely, the volume minimum that sustains that exclusivity, and the consequences if the minimum is not met. Blanket exclusivity without a volume floor is a liability for the LP and offers the buyer security without commitment.
Compliance obligations that belong in the contract, not a handshake
Verbal assurances about regulatory compliance are not enforceable. The following obligations should appear as express representations and warranties in the supply agreement.
Licence verification and maintenance
Both parties should represent that they hold valid licences under the Cannabis Act and Cannabis Regulations as of the effective date. Include a mutual obligation to notify the other party within a specified number of days (typically 2 to 5 business days) if the licence is amended, suspended, or revoked. Automatic termination rights tied to loss of licence are standard in well-drafted agreements and protect both parties from unwittingly breaching the Cannabis Act.
GMP and quality system compliance
For agreements involving international supply, the exporting LP should warrant that it operates under a GMP framework equivalent to EU-GMP or Health Canada GMP, and that its quality system is current and uncontested. If EU-GMP certification is a condition of the supply relationship, make it an express warranty with a cure period and termination right if certification lapses. Our breakdown of EU-GMP certification for Canadian LPs covers what that certification entails and how it maps to Health Canada requirements.
Export permit conditions
Canadian export permits issued by Health Canada under the Cannabis Act contain conditions. Those conditions may restrict the importing country, require specific packaging or labelling, or limit the product form. The supply agreement should confirm that all shipments will comply with current permit conditions, include an obligation to notify the buyer if conditions change, and allocate the risk of a permit amendment that makes performance impossible or commercially unreasonable.
GACP and traceability
For markets like Germany, Australia, and Israel that increasingly expect Good Agricultural and Collection Practice (GACP) documentation, the contract should require the LP to maintain and provide GACP-aligned records on request. Full batch traceability, from seed or clone to final packaged unit, is becoming a baseline expectation in pharmaceutical-grade supply channels rather than a premium add-on.
Regulatory change allocation
A regulatory force majeure clause should cover material changes to the Cannabis Act, Health Canada licence conditions, importing country regulations, or any permit condition that makes performance commercially impossible. This clause is distinct from a standard force majeure clause covering natural disasters or war. Cannabis supply agreements deserve both.
Red flags in cannabis supply agreements and how to avoid them
These are the provisions and absences that most often produce disputes or leave one party exposed.
No dispute resolution mechanism for COA disagreements
When a buyer rejects a batch and the LP disputes the COA result, the only resolution path that does not involve litigation is a pre-agreed retesting process with a named third-party lab. Agreements that are silent on this leave the parties in a standoff. Specify the lab, the standard, and who bears the cost of retesting (typically the losing party in a binding arbitration model).
Ambiguous product specification
Describing the product as "premium cannabis flower" without specifying cultivar, format, potency floor, or COA parameters creates a delivery standard that neither party can enforce or defend. Every measurable quality attribute that influences the purchase decision should appear in the specification schedule attached to the agreement.
No licence verification obligation
Agreements that assume both parties hold valid licences without requiring verification or ongoing notification create legal exposure. A buyer purchasing from an LP whose licence has been suspended, even unknowingly, may be in breach of the Cannabis Act. The verification obligation and notification window should be express, not implied.
Missing or weak termination provisions
A supply agreement with no clear termination rights other than material breach leaves both parties exposed to an underperforming relationship with no clean exit. Include termination for convenience with a defined notice period, termination for cause with a cure window, and automatic termination triggers for licence loss. Sunset clauses on multi-year agreements are worth considering in a regulatory environment that continues to evolve.
No consideration for batch size variability
Cannabis is an agricultural product. Batch weights, bud size distribution, and potency vary across harvests. A contract that commits to exact gram weights without a tolerance range will produce a technical breach on almost every delivery. Build in yield tolerance bands (typically plus or minus 5 to 10 percent of the committed volume) and define how shortfalls are handled: credited forward, replaced in the next delivery, or released from obligation.
AlphaLeaf operates as a Health Canada Licensed Producer of premium B2B dried cannabis flower from our Montreal indoor facility. Our supply agreements are built on full batch traceability, ISO/IEC 17025-certified third-party testing, and EU-GMP-aligned quality systems. We work with importers and distribution partners in Germany, Australia, Israel, and beyond who expect documentation, consistency, and a supplier that understands how contracts and compliance interact. If you are building or reviewing a cannabis supply framework for your procurement programme, we welcome the conversation.
Frequently Asked Questions
What should a cannabis B2B supply agreement include?
A cannabis B2B supply agreement should include product specifications (strain, format, minimum THC/CBD thresholds), volume commitments, COA acceptance criteria, delivery terms, licence verification obligations, batch rejection and dispute resolution clauses, force majeure provisions covering regulatory changes, and any export permit conditions where applicable.
Do Canadian cannabis supply agreements need to reference the Cannabis Act?
Yes. Every commercial cannabis transaction in Canada is governed by the Cannabis Act and Cannabis Regulations. Supply agreements between LPs should explicitly reference these statutes, confirm that both parties hold valid Health Canada licences, and include a clause requiring immediate notification if either party's licence is suspended, amended, or revoked.
What is an offtake agreement in the cannabis industry?
An offtake agreement in cannabis is a pre-production supply contract where a buyer commits to purchasing a specified volume of cannabis flower or extract at a set price for a defined period, often tied to a specific growing cycle or facility output. It provides revenue certainty for the LP and supply security for the buyer, and typically includes minimum purchase commitments and pricing adjustment mechanisms.
How should batch rejection be handled in a cannabis supply contract?
Batch rejection clauses should specify the window for rejection after delivery, the COA thresholds that trigger a rejection, who bears return shipping costs, and the LP's obligation to replace or credit the rejected batch. A well-drafted clause also addresses disputed results by naming an agreed third-party ISO 17025-accredited lab for retesting.
What happens to a cannabis supply agreement if Health Canada changes export conditions?
A properly drafted cannabis supply agreement includes a regulatory force majeure clause that treats material changes to Health Canada export permit conditions, Cannabis Act amendments, or the importing country's regulatory framework as qualifying events that may suspend, renegotiate, or terminate the agreement without penalty to the affected party. Without this clause, one party may bear all the financial risk of a regulatory shift beyond their control.
